Search results for " hypogonadism"

showing 10 items of 12 documents

Sema3a plays a role in the pathogenesis of CHARGE syndrome

2018

CHARGE syndrome is an autosomal dominant malformation disorder caused by heterozygous loss of function mutations in the chromatin remodeler CHD7. Chd7 regulates the expression of Sema3a, which also contributes to the pathogenesis of Kallmann syndrome, a heterogeneous condition with the typical features hypogonadotropic hypogonadism and an impaired sense of smell. Both features are common in CHARGE syndrome suggesting that SEMA3A may provide a genetic link between these syndromes. Indeed, we find evidence that SEMA3A plays a role in the pathogenesis of CHARGE syndrome. First, Chd7 is enriched at the Sema3a promotor in neural crest cells and loss of function of Chd7 inhibits Sema3a expression…

0301 basic medicineEmbryo NonmammalianKallmann syndromePHENOTYPIC SPECTRUMmedicine.disease_causeSeverity of Illness IndexEpigenesis GeneticPathogenesisAXON GUIDANCECHD7CHARGE syndromeXenopus laevis0302 clinical medicineHYPOGONADOTROPIC HYPOGONADISMPromoter Regions GeneticGenetics (clinical)GeneticsMutationGeneral MedicinePhenotypeDNA-Binding ProteinsNEURAL CREST CELLSNeural CrestHomeobox Protein Nkx-2.5MIGRATIONBiology03 medical and health sciencesHypogonadotropic hypogonadismKALLMANN-SYNDROMEGeneticsmedicineAnimalsHumansEpigeneticsSHORT STATUREMolecular BiologyLoss functionMUTATIONSGenetic Complementation TestDNA HelicasesSemaphorin-3AKallmann Syndromemedicine.diseaseDisease Models Animal030104 developmental biologyHEK293 CellsXENOPUS-EMBRYOSMutationCHARGE Syndrome030217 neurology & neurosurgery
researchProduct

NKX2-1 New Mutation Associated With Myoclonus, Dystonia, and Pituitary Involvement

2018

Background: NKX2-1 related disorders (also known as brain-lung-thyroid syndrome or benign hereditary chorea 1) are associated with a wide spectrum of symptoms. The core features are various movement disorders, characteristically chorea, less frequently myoclonus, dystonia, ataxia; thyroid disease; and lung involvement. The full triad is present in 50% of affected individuals. Numerous additional symptoms may be associated, although many of these were reported only in single cases. Pituitary dysfunction was ambiguously linked to NKX2-1 haploinsufficiency previously. Case Presentation: We examined two members of a family with motor developmental delay, mixed movement disorder (myoclonus, dyst…

0301 basic medicinePediatricsmedicine.medical_specialtycongenital hereditary and neonatal diseases and abnormalitiesMovement disordersAtaxialcsh:QH426-470NKX2-1 geneCase Reportbenign hereditary choreapituitary03 medical and health sciences0302 clinical medicineBenign hereditary choreamyoclonus dystoniaHypogonadotropic hypogonadismmedicineGeneticschoreaGenetics (clinical)Dystoniabusiness.industryChoreabrain-lung-thyroid syndromemedicine.diseasenervous system diseaseslcsh:Genetics030104 developmental biologyNKX2-1 related disordersempty sellaMolecular Medicinemedicine.symptombusinessHaploinsufficiencyMyoclonus030217 neurology & neurosurgeryFrontiers in Genetics
researchProduct

Transfusional Hemochromatosis: Quantitative Relation of MR Imaging Pituitary Signal Intensity Reduction to Hypogonadotropic Hypogonadism

2000

To assess the relationship between magnetic resonance (MR) imaging pituitary signal intensity reduction in patients with transfusional hemochromatosis and the clinical manifestation of hypogonadotropic hypogonadism.Pituitary MR imaging at 0.5 T was performed in 38 consecutive patients affected by secondary hemochromatosis and in 20 healthy volunteers. Serum ferritin levels were estimated in the affected population. Twenty (53%) of the 38 patients had hypogonadotropic hypogonadism diagnosed. Pituitary-to-fat signal intensity ratios were calculated from coronal gradient-echo (GRE) T2*-weighted MR images. The relationship between the quantitative reduction of the pituitary-to-fat signal intens…

AdultMalePathologymedicine.medical_specialtyPituitary glandAdolescentHemochromatosiPopulationSensitivity and SpecificityPituitary Gland AnteriorHypogonadotropic hypogonadismmedicineHumansBlood TransfusionRadiology Nuclear Medicine and imagingChildeducationHemochromatosisFerritineducation.field_of_studymedicine.diagnostic_testbusiness.industryHypogonadismbeta-ThalassemiaTransfusion ReactionBeta thalassemiaMagnetic resonance imagingmedicine.diseaseMagnetic Resonance Imagingmedicine.anatomical_structureROC CurveCoronal planeFerritinsFemaleHemochromatosisbusinessNuclear medicineHumanHormoneRadiology
researchProduct

Lower sperm DNA fragmentation after r-FSH administration in functional hypogonadotropic hypogonadism

2013

Abstract PURPOSE: An observational clinical and molecular study was designed to evaluate the effects of the administration of recombinant human FSH on sperm DNA fragmentation in men with a non-classical form of hypogonadotropic hypogonadism and idiopathic oligoasthenoteratozoospermia. METHODS: In the study were included 53 men with a non-classical form of hypogonadotropic hypogonadism and idiopathic oligoasthenoteratozoospermia. In all patients, sperm DNA fragmentation index (DFI), assessed by terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate (dUTP) in situ DNA nick end-labelling (TUNEL) assay, was evaluated before starting the treatment with 150 IU of recombinant hum…

AdultMaleendocrine systemmedicine.medical_specialtyDNA FragmentationAsthenozoospermialaw.inventionAndrologyHypogonadotropic hypogonadismlawGamete BiologyInternal medicineGeneticsmedicineHumansApoptosis Gametogenesis DNA SpermSettore BIO/06 - Anatomia Comparata E CitologiaGenetics (clinical)GametogenesisSperm Countbusiness.industryHypogonadismObstetrics and GynecologyOligospermiaGeneral Medicinemedicine.diseaseSpermatozoaSpermRecombinant ProteinsEndocrinologyReproductive MedicineAsthenozoospermiaOligospermiaApoptosisRecombinant DNADNA fragmentationFollicle Stimulating Hormone HumanbusinessDevelopmental Biology
researchProduct

Subcutaneous gonadotropin therapy in male patients with hypogonadotropic hypogonadism

1991

Objective The response to subcutaneous (SC) gonadotropin replacement therapy, using human chorionic gonadotropin (hCG) and human menopausal gonadotropin (hMG) or hCG alone, was evaluated in male hypothalamic hypogonadism. Design Sixteen patients with hypothalamic hypogonadism were treated with gonadotropins for induction of puberty and normalization of spermatogenesis. The results were analyzed retrospectively. Setting The study was carried out in a clinical endocrinology department providing tertiary care and in private practices of endocrinology. Patients Eight patients with idiopathic hypogonadotropic hypogonadism and eight patients with Kallmann's syndrome in prepubertal or early pubert…

AdultMaleendocrine systemmedicine.medical_specialtyMenotropinsAdolescentmedicine.drug_classmedicine.medical_treatmentChorionic GonadotropinInjections IntramuscularHuman chorionic gonadotropinSemen qualityHypogonadotropic hypogonadismInternal medicineTestisHumansMedicineEunuchismTestosteroneSexual MaturationSpermatogenesisRetrospective StudiesChemotherapybiologyurogenital systembusiness.industryHypogonadismObstetrics and Gynecologymedicine.diseaseSpermEndocrinologyReproductive MedicineHMG-CoA reductasebiology.proteinDrug Therapy CombinationGonadotropinbusinessSpermatogenesisFertility and Sterility
researchProduct

Testicular Sperm Extraction (TESE) and Intracytoplasmic Sperm Injection (ICSI) in Hypogonadotropic Hypogonadism with Persistent Azoospermia After Hor…

2004

Purpose: We aimed to retrieve testicular sperm to be employed on intracytoplasmic sperm injection (ICSI) cycles on a male affected of hypogonadotropic hypogonadism (HH) that remained azoospermic after long-time hormonal treatment. Methods: Design. We initially performed hormonal therapy using gonadotropins to achieve spermatogenesis. After several semen analyses, we weighed the possibility of looking for testicular spermatozoa for ICSI. Setting. A private university-affiliated setting. Patient. A 30-years-old man diagnosed 10 years ago to suffer from idiopathic, prepubertal HH. Interventions. Gonadotrophin treatment was initiated with hCG and follicle stimulating hormone (FSH). Testicular s…

AdultMaleendocrine systemmedicine.medical_treatmentSemenArticleIntracytoplasmic sperm injectionGonadotropin-Releasing HormoneAndrologyFollicle-stimulating hormonePregnancyHypogonadotropic hypogonadismGeneticsmedicineHumansTestosteroneSperm Injections IntracytoplasmicSpermatogenesisreproductive and urinary physiologyGenetics (clinical)CryopreservationAzoospermiaurogenital systembusiness.industryHypogonadismPregnancy OutcomeObstetrics and GynecologyOligospermiaGeneral MedicineLuteinizing Hormonemedicine.diseaseSpermatozoaSpermTesticular sperm extractionReproductive MedicineFemaleFollicle Stimulating HormoneLuteinizing hormonebusinesshormones hormone substitutes and hormone antagonistsSemen PreservationDevelopmental BiologyJournal of Assisted Reproduction and Genetics
researchProduct

HeterozygousFGF8mutations in patients presenting cryptorchidism and multiple VATER/VACTERL features without limb anomalies

2014

Background The acronym VATER/VACTERL association describes the combination of at least three of the following cardinal features: vertebral defects, anorectal malformations, cardiac defects, tracheoesophageal fistula with or without esophageal atresia, renal malformations, and limb defects. Although fibroblast growth factor-8 (FGF8) mutations have mainly found in patients with Kallmann syndrome, mice with a hypomorphic Fgf8 allele or complete gene invalidation display, aside from gonadotropin-releasing hormone deficiency, parts or even the entire spectrum of human VATER/VACTERL association. Methods We performed FGF8 gene analysis in 49 patients with VATER/VACTERL association and 27 patients …

Delayed pubertyEmbryologymedicine.medical_specialtyKallmann syndromeTracheoesophageal fistulaGeneral MedicineBiologyUnilateral cryptorchidismmedicine.diseaseVACTERL associationGastroenterologyHypergonadotropic hypogonadismEndocrinologyInternal medicineAtresiaPediatrics Perinatology and Child HealthGene duplicationmedicinemedicine.symptomDevelopmental BiologyBirth Defects Research Part A: Clinical and Molecular Teratology
researchProduct

Gonadotropic Therapy in Men with Hypogonadotropic Hypogonadism

1984

Many therapeutic regimens, differing in dose and duration, have been employed in the treatment of hypogonadotropic hypogonadism. This study presents the results from a regimen of hCG plus hMG plus testosterone combined treatment in 15 patients affected by selective hypogonadotropic hypogonadism. The patients were homogeneous in age (16–23 years), testicular size, aspermia, absence of prior hormonal treatment, and normal karyotype. They were administered 5000 IU of hCG plus 75 IU of hMG twice a week for two months and a single dose of depo-testosterone (250 mg) in the third month. This therapeutic plan was carried out continuously for eight three-month cycles (24 months). Sexual maturation a…

GynecologyAzoospermiamedicine.medical_specialtymedicine.drug_classSecondary sex characteristicbusiness.industryUrologyEndocrinology Diabetes and MetabolismUrologyAspermiamedicine.diseaseRegimenEndocrinologymedicine.anatomical_structureReproductive MedicineHypogonadotropic hypogonadismScrotummedicineGonadotropinbusinessTestosteroneJournal of Andrology
researchProduct

Aromatase Inhibitors Plus Weight Loss Improves the Hormonal Profile of Obese Hypogonadal Men Without Causing Major Side Effects

2020

Objective: In obese men, the increased expression of the aromatase enzyme in adipose tissue leads to high conversion of androgens to estrogens contributing to hypogonadotropic hypogonadism (HHG). Our objective is to evaluate efficacy and safety of weight loss (WL) plus aromatase inhibitor (AI) therapy in severely obese men with HHG. We hypothesize that AI+WL will be more effective as compared to WL alone in improving the hormonal profile, thus muscle strength and symptoms of HHG (primary outcomes), with no significant adverse effects on lean mass, metabolic profile, and bone mineral density (secondary outcomes).Design: Randomized double-blind placebo-controlled pilot trial.Methods: Twenty-t…

Male0301 basic medicineobesityBone densityEndocrinology Diabetes and MetabolismPilot Projectslcsh:Diseases of the endocrine glands. Clinical endocrinologyaromatase inhibitorsEndocrinology0302 clinical medicineBone DensityWeight lossMedicineTestosteroneTestosteroneBone mineralEstradiolMiddle AgedPrognosisClinical TrialAndrogensMetabolomemedicine.symptombone microarchitecturemedicine.drugAdultmedicine.medical_specialtyHormone Replacement Therapymedicine.drug_classAnastrozole030209 endocrinology & metabolismsex hormonesBone and Bones03 medical and health sciencesDouble-Blind MethodHypogonadotropic hypogonadismInternal medicineWeight LossHumanshypogonadismMuscle StrengthAgedbody compositionlcsh:RC648-665Aromatase inhibitorbusiness.industrymedicine.disease030104 developmental biologyEndocrinologyLean body massbusinessBiomarkersFollow-Up StudiesFrontiers in Endocrinology
researchProduct

GERMLINE PROKINETICIN RECEPTOR 2 (PROKR2) VARIANTS ASSOCIATED WITH CENTRAL HYPOGONADISM CAUSE DIFFERENTAL MODULATION OF DISTINCT INTRACELLULAR PATHWA…

2013

INTRODUCTION: Defects of prokineticin pathway affect the neuroendocrine control of reproduction, but their role in the pathogenesis of central hypogonadism remains undefined, and the functional impact of the missense PROKR2 variants has been incompletely characterized. MATERIAL AND METHODS: In a series of 246 idiopathic central hypogonadism patients, we found three novel (p.V158I, p.V334M, and p.N15TfsX30) and six already known (p.L173R, p.T260M, p.R268C, p.V274D, p.V331M, and p.H20MfsX23) germline variants in the PROKR2 gene. We evaluated the effects of seven missense alterations on two different prokineticin receptor 2 (PROKR2)-dependent pathways: inositol phosphate-Ca(2+) (Gq coupling) a…

MaleKallmann syndromeEndocrinology Diabetes and MetabolismClinical BiochemistryInositol Phosphatemedicine.disease_causeBiochemistryHypogonadotropic hypogonadismGermlineReceptors G-Protein-CoupledCohort StudiesEndocrinologySettore MED/38 - Pediatria Generale E SpecialisticaAdolescent; Adult; Child; Cohort Studies; Cyclic AMP; Female; Genetic Association Studies; Humans; Hypogonadism; Inositol Phosphates; Male; Middle Aged; Mutation Missense; Receptors G-Protein-Coupled; Receptors Peptide; Signal Transduction; Young Adult; Germ-Line MutationReceptorsCyclic AMPmutations; Kallmann syndrome; septo-optic dysplasiaMissense mutationReceptorChildMutationMiddle AgedProkineticinPeptideFemaleHumanSignal TransductionAdultmedicine.medical_specialtyReceptors PeptideAdolescentAdolescent Adult Child Cohort Studies Cyclic AMP; metabolism Female Genetic Association Studies Germ-Line Mutation Humans Hypogonadism; epidemiology/genetics Inositol Phosphates; metabolism Male Middle Aged Missense Receptors; G-Protein-Coupled; genetics Receptors; Peptide; genetics Signal Transduction; genetics Young AdultInositol PhosphatesMutation MissenseGenetic Association StudieBiologyG-Protein-CoupledYoung AdultGermline mutationInternal medicinesepto-optic dysplasiamedicineHumansGenetic Association StudiesGerm-Line MutationHypogonadismBiochemistry (medical)Kallmann syndromeProkineticin receptor 2medicine.diseasePROKR2 hypogonadism prokineticinmutationsAdolescent; Adult; Child; Cohort Studies; Cyclic AMP; Female; Genetic Association Studies; Humans; Hypogonadism; Inositol Phosphates; Male; Middle Aged; Mutation; Missense; Receptors; G-Protein-Coupled; Peptide; Signal Transduction; Young Adult; Germ-Line MutationEndocrinologyMutationCohort StudieMissense
researchProduct